| Year |
Citation |
Score |
| 2023 |
Wang L, Yi W, Ma L, Lecea E, Hazlehurst LA, Adjeroh DA, Hu G. Inflammatory Bone Marrow Mesenchymal Stem Cells in Multiple Myeloma: Transcriptional Signature and In Vitro Modeling. Cancers. 15. PMID 37958322 DOI: 10.3390/cancers15215148 |
0.314 |
|
| 2022 |
Jones C, Dziadowicz S, Suite S, Eby A, Chen WC, Hu G, Hazlehurst LA. Emergence of Resistance to MTI-101 Selects for a MET Genotype and Phenotype in EGFR Driven PC-9 and PTEN Deleted H446 Lung Cancer Cell Lines. Cancers. 14. PMID 35804837 DOI: 10.3390/cancers14133062 |
0.375 |
|
| 2022 |
Dziadowicz SA, Wang L, Akhter H, Aesoph D, Sharma T, Adjeroh DA, Hazlehurst LA, Hu G. Bone Marrow Stroma-Induced Transcriptome and Regulome Signatures of Multiple Myeloma. Cancers. 14. PMID 35205675 DOI: 10.3390/cancers14040927 |
0.377 |
|
| 2020 |
Jain P, Badger DB, Liang Y, Gebhard AW, Santiago D, Murray P, Kaulagari SR, Gauthier TJ, Nair R, Kumar M, Guida WC, Hazlehurst LA, McLaughlin ML. Bioactivity improvement via display of the hydrophobic core of HYD1 in a cyclic β-hairpin-like scaffold, MTI-101. Peptide Science (Hoboken, N.J.). 113: e24199. PMID 35859761 DOI: 10.1002/pep2.24199 |
0.724 |
|
| 2020 |
Chen WC, Hu G, Hazlehurst LA. Contribution of the bone marrow stromal cells in mediating drug resistance in hematopoietic tumors. Current Opinion in Pharmacology. 54: 36-43. PMID 32898723 DOI: 10.1016/j.coph.2020.08.006 |
0.39 |
|
| 2020 |
Freeman S, Elzamzamy O, Geldenhuys W, Hazlehurst L. CLIC1 is an Attractive Candidate for the Initial Binding Target of the Novel Peptide MTI‐101 The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.01945 |
0.304 |
|
| 2019 |
Toth RK, Tran JD, Muldong MT, Nollet EA, Schulz VV, Jensen CC, Hazlehurst LA, Corey E, Durden D, Jamieson C, Miranti CK, Warfel NA. Hypoxia-induced PIM kinase and laminin-activated integrin α6 mediate resistance to PI3K inhibitors in bone-metastatic CRPC. American Journal of Clinical and Experimental Urology. 7: 297-312. PMID 31511835 |
0.38 |
|
| 2019 |
Chen W, Hazlehurst L. Abstract 852: Determining the roles of ERO1-alpha and ERO1-beta in progression of multiple myeloma and drug resistance Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-852 |
0.319 |
|
| 2018 |
Sweet K, Hazlehurst L, Sahakian E, Powers J, Nodzon L, Kayali F, Hyland K, Nelson A, Pinilla-Ibarz J. A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease. Leukemia Research. 74: 89-96. PMID 30340199 DOI: 10.1016/J.Leukres.2018.10.002 |
0.391 |
|
| 2018 |
von Roemeling CA, Caulfield TR, Marlow L, Bok I, Wen J, Miller JL, Hughes R, Hazlehurst L, Pinkerton AB, Radisky DC, Tun HW, Kim YSB, Lane AL, Copland JA. Accelerated bottom-up drug design platform enables the discovery of novel stearoyl-CoA desaturase 1 inhibitors for cancer therapy. Oncotarget. 9: 3-20. PMID 29416592 DOI: 10.18632/Oncotarget.21545 |
0.328 |
|
| 2017 |
Chen WC, Kanate AS, Craig M, Petros WP, Hazlehurst LA. Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab. Cancer Management and Research. 9: 307-314. PMID 28744161 DOI: 10.2147/CMAR.S117477 |
0.33 |
|
| 2017 |
Emmons MF, Anreddy N, Cuevas J, Steinberger K, Yang S, McLaughlin M, Silva A, Hazlehurst LA. MTI-101 treatment inducing activation of Stim1 and TRPC1 expression is a determinant of response in multiple myeloma. Scientific Reports. 7: 2685. PMID 28578393 DOI: 10.1038/S41598-017-02713-0 |
0.355 |
|
| 2017 |
Li X, Nelson CG, Nair RR, Hazlehurst L, Moroni T, Martinez-Acedo P, Nanna AR, Hymel D, Burke TR, Rader C. Stable and Potent Selenomab-Drug Conjugates. Cell Chemical Biology. PMID 28330604 DOI: 10.1016/J.Chembiol.2017.02.012 |
0.307 |
|
| 2016 |
Anreddy N, Hazlehurst LA. Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma. Journal of Cellular Biochemistry. PMID 27261328 DOI: 10.1002/jcb.25617 |
0.325 |
|
| 2016 |
Sweet KL, Hazlehurst L, Sahakian E, Powers JJ, Nodzon L, Kayali F, Hyland K, Nelson A, Pinilla-Ibarz J. A Phase I Study of Ruxolitinib Plus Nilotinib in Chronic Phase CML Patients with Molecular Evidence of Disease Blood. 128: 1892-1892. DOI: 10.1182/Blood.V128.22.1892.1892 |
0.338 |
|
| 2015 |
Shay G, Hazlehurst L, Lynch CC. Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities. Journal of Molecular Medicine (Berlin, Germany). PMID 26423531 DOI: 10.1007/S00109-015-1345-4 |
0.427 |
|
| 2015 |
Meads MB, Fang B, Mathews L, Gemmer J, Nong L, Rosado-Lopez I, Nguyen T, Ring JE, Matsui W, MacLeod AR, Pachter JA, Hazlehurst LA, Koomen JM, Shain KH. Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma. Oncogene. PMID 26387544 DOI: 10.1038/Onc.2015.334 |
0.403 |
|
| 2015 |
Emmons M, Hazlehurst L, Escherich S, McLaughlin M, Cuevas J, Sullivan D. Abstract 4439: Ero1L is a determinant of resistance to bortezomib and collateral sensitivity to MTI-101-induced cell death in myeloma Cancer Research. 75: 4439-4439. DOI: 10.1158/1538-7445.Am2015-4439 |
0.422 |
|
| 2015 |
Yang H, Emmons MF, Cubitt C, Shain K, Coppola D, Sullivan D, Lynch CC, Hazlehurst L, Sebti SM. Abstract 2605: The geranylgeranyltransferase I inhibitor GGTI-2418 suppresses multiple myeloma malignancy in the 5TMG1 mouse model Cancer Research. 75: 2605-2605. DOI: 10.1158/1538-7445.Am2015-2605 |
0.347 |
|
| 2014 |
Khin ZP, Ribeiro ML, Jacobson T, Hazlehurst L, Perez L, Baz R, Shain K, Silva AS. A preclinical assay for chemosensitivity in multiple myeloma. Cancer Research. 74: 56-67. PMID 24310398 DOI: 10.1158/0008-5472.Can-13-2397 |
0.417 |
|
| 2014 |
Shain KH, Meads MB, Fang B, Mathews L, Gemmer J, Nong L, Rosado-Lopez I, Ring JE, MacLeod R, Hazlehurst L, Lynch C, Pachter JA, Matsui W, Koomen J, Nguyen T. Targeting PYK2 Mediates Microenvironment-Specific Myeloma Cell Death Blood. 124: 2081-2081. DOI: 10.1182/Blood.V124.21.2081.2081 |
0.468 |
|
| 2014 |
Meads MB, Fang B, Mathews L, Gemmer J, Nong L, MacCleod R, Hazlehurst L, Koomen J, Shain KH. Abstract 4892: PYK2 mediates microenvironment-specific myeloma survival Cancer Research. 74: 4892-4892. DOI: 10.1158/1538-7445.Am2014-4892 |
0.456 |
|
| 2014 |
Blumencranz LE, Nair RR, McLaughlin ML, Haura EB, Hazlehurst LA. Abstract A07: MTI-101 induces synergistic cell kill in combination with Erlotinib in EGFR-driven lung cancer models. Clinical Cancer Research. 20: A07-A07. DOI: 10.1158/1078-0432.14Aacriaslc-A07 |
0.318 |
|
| 2013 |
Turner JG, Dawson J, Emmons MF, Cubitt CL, Kauffman M, Shacham S, Hazlehurst LA, Sullivan DM. CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo. Journal of Cancer. 4: 614-25. PMID 24155773 DOI: 10.7150/Jca.7080 |
0.4 |
|
| 2013 |
Gebhard AW, Jain P, Nair RR, Emmons MF, Argilagos RF, Koomen JM, McLaughlin ML, Hazlehurst LA. MTI-101 (cyclized HYD1) binds a CD44 containing complex and induces necrotic cell death in multiple myeloma. Molecular Cancer Therapeutics. 12: 2446-58. PMID 24048737 DOI: 10.1158/1535-7163.Mct-13-0310 |
0.772 |
|
| 2013 |
Sweet KL, Hazlehurst LA, Pinilla-Ibarz J. The one-two punch: combination treatment in chronic myeloid leukemia. Critical Reviews in Oncology/Hematology. 88: 667-79. PMID 23969231 DOI: 10.1016/J.Critrevonc.2013.07.017 |
0.338 |
|
| 2013 |
Schonbrunn E, Betzi S, Alam R, Martin MP, Becker A, Han H, Francis R, Chakrasali R, Jakkaraj S, Kazi A, Sebti SM, Cubitt CL, Gebhard AW, Hazlehurst LA, Tash JS, et al. Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases. Journal of Medicinal Chemistry. 56: 3768-82. PMID 23600925 DOI: 10.1021/Jm301234K |
0.73 |
|
| 2013 |
Meads M, Fang B, Mathews L, Gemmer J, Nong L, Hazlehurst LA, MacLeod R, Koomen J, Shain K. PYK2 Mediates Microenvironment-Specific Myeloma Survival Blood. 122: 4443-4443. DOI: 10.1182/Blood.V122.21.4443.4443 |
0.41 |
|
| 2013 |
Zhang X, Sweet KL, Moscinski L, Hazlehurst LA, Pinilla-Ibarz J, Zhang L. Bone Marrow Beta-Catenin Expression In Chronic Myelogenous Leukemia Patients Treated With Imatinib Blood. 122: 2739-2739. DOI: 10.1182/Blood.V122.21.2739.2739 |
0.308 |
|
| 2012 |
Nair RR, Gebhard AW, Emmons MF, Hazlehurst LA. Emerging strategies for targeting cell adhesion in multiple myeloma. Advances in Pharmacology (San Diego, Calif.). 65: 143-89. PMID 22959026 DOI: 10.1016/B978-0-12-397927-8.00006-3 |
0.755 |
|
| 2012 |
Nair RR, Tolentino JH, Hazlehurst LA. Role of STAT3 in Transformation and Drug Resistance in CML. Frontiers in Oncology. 2: 30. PMID 22649784 DOI: 10.3389/fonc.2012.00030 |
0.373 |
|
| 2012 |
Nair RR, Tolentino JH, Argilagos RF, Zhang L, Pinilla-Ibarz J, Hazlehurst LA. Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML. Leukemia Research. 36: 756-63. PMID 22209738 DOI: 10.1016/J.Leukres.2011.12.002 |
0.393 |
|
| 2012 |
Nair RR, Tolentino JH, Ugrenovic M, Jain PR, McLaughlin ML, Lancet JE, Hazlehurst LA. Mti-101 Induces Necrotic Cell Death in AML Cells Through Its Binding to Cell Surface Complexes Containing CD44 and ITGA4 Blood. 120: 869-869. DOI: 10.1182/Blood.V120.21.869.869 |
0.41 |
|
| 2012 |
Gebhard AW, Nair RR, Emmons M, Jain PR, Becker A, Koomen J, Schonbrunn E, Sullivan DM, McLaughlin ML, Hazlehurst LA. Mti-101 (cyclized HYD1) Binds to CD44 and Induces Necrotic Cell Death in Multiple Myeloma Blood. 120: 4022-4022. DOI: 10.1182/Blood.V120.21.4022.4022 |
0.751 |
|
| 2012 |
Silva AS, Khin Z, Shain KH, Baz R, Hazlehurst LA, Durand A, Gatenby R. Personalizing Myeloma Chemotherapy Using Evolutionary Computational Models and Ex Vivo Assays. Blood. 120: 2960-2960. DOI: 10.1182/blood.v120.21.2960.2960 |
0.324 |
|
| 2012 |
Khin Z, Hazlehurst L, Shain K, Gillies R, Gatenby R, Silva AS. Abstract 3194: Reverse engineering the interplay between multiple myeloma and microenvironment Cancer Research. 72: 3194-3194. DOI: 10.1158/1538-7445.Am2012-3194 |
0.436 |
|
| 2011 |
Emmons MF, Gebhard AW, Nair RR, Baz R, McLaughlin ML, Cress AE, Hazlehurst LA. Acquisition of resistance toward HYD1 correlates with a reduction in cleaved α4 integrin expression and a compromised CAM-DR phenotype. Molecular Cancer Therapeutics. 10: 2257-66. PMID 21980133 DOI: 10.1158/1535-7163.Mct-11-0149 |
0.787 |
|
| 2011 |
Xiang Y, Remily-Wood ER, Oliveira V, Yarde D, He L, Cheng JQ, Mathews L, Boucher K, Cubitt C, Perez L, Gauthier TJ, Eschrich SA, Shain KH, Dalton WS, Hazlehurst L, et al. Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma. Molecular & Cellular Proteomics : McP. 10: M110.005520. PMID 21846842 DOI: 10.1074/Mcp.M110.005520 |
0.452 |
|
| 2011 |
Remily-Wood ER, Liu RZ, Xiang Y, Chen Y, Thomas CE, Rajyaguru N, Kaufman LM, Ochoa JE, Hazlehurst L, Pinilla-Ibarz J, Lancet J, Zhang G, Haura E, Shibata D, Yeatman T, et al. A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer. Proteomics. Clinical Applications. 5: 383-96. PMID 21656910 DOI: 10.1002/Prca.201000115 |
0.32 |
|
| 2011 |
Emmons MF, Gebhard A, Mclaughlin M, Cress A, Hazlehurst L. Abstract 1523: α4 integrin expression is a determinant for activity of the integrin antagonist HYD1 in multiple myeloma cell lines and patient specimens Cancer Research. 71: 1523-1523. DOI: 10.1158/1538-7445.Am2011-1523 |
0.769 |
|
| 2010 |
Nair RR, Tolentino J, Hazlehurst LA. The bone marrow microenvironment as a sanctuary for minimal residual disease in CML. Biochemical Pharmacology. 80: 602-12. PMID 20382130 DOI: 10.1016/j.bcp.2010.04.003 |
0.317 |
|
| 2010 |
Emmons M, Nair R, McLaughlin M, Eschrich S, Cress A, Hazlehurst L. Abstract 1547: Acquisition of resistance to the β1 integrin antagonist HYD1 correlates with decreased α4, α6, αV and β1 integrin expression and decreased adhesion to fibronectin, VCAM-1 and vitronectin Cancer Research. 70: 1547-1547. DOI: 10.1158/1538-7445.Am10-1547 |
0.498 |
|
| 2009 |
Yarde DN, Oliveira V, Mathews L, Wang X, Villagra A, Boulware D, Shain KH, Hazlehurst LA, Alsina M, Chen DT, Beg AA, Dalton WS. Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Research. 69: 9367-75. PMID 19934314 DOI: 10.1158/0008-5472.Can-09-2616 |
0.342 |
|
| 2009 |
Turner JG, Marchion DC, Dawson JL, Emmons MF, Hazlehurst LA, Washausen P, Sullivan DM. Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition. Cancer Research. 69: 6899-905. PMID 19690141 DOI: 10.1158/0008-5472.Can-09-0484 |
0.343 |
|
| 2009 |
Hazlehurst LA, Bewry NN, Nair RR, Pinilla-Ibarz J. Signaling networks associated with BCR-ABL-dependent transformation. Cancer Control : Journal of the Moffitt Cancer Center. 16: 100-7. PMID 19337196 DOI: 10.1177/107327480901600202 |
0.688 |
|
| 2008 |
Bewry NN, Nair RR, Emmons MF, Boulware D, Pinilla-Ibarz J, Hazlehurst LA. Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Molecular Cancer Therapeutics. 7: 3169-75. PMID 18852120 DOI: 10.1158/1535-7163.Mct-08-0314 |
0.724 |
|
| 2008 |
Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 2519-26. PMID 18451212 DOI: 10.1158/1078-0432.CCR-07-2223 |
0.406 |
|
| 2008 |
Hazlehurst L, Dalton WS, Yarde D, Nefedova Y, Gabrilovich D. Influence of Targeted Therapy in Redefining High-Risk Myeloma. Blood. 112: sci-7-sci-7. DOI: 10.1182/Blood.V112.11.Sci-7.Sci-7 |
0.53 |
|
| 2008 |
Shain KH, Yarde D, Mead M, Hazlehurst L, Dalton WS. β1 Integrin Adhesion Enhances IL-6 Mediated STAT3 Signaling in Multiple Myeloma Cells: Implications for Microenvironment Influence on Tumor Cell Survival and Proliferation. Blood. 112: 1706-1706. DOI: 10.1182/Blood.V112.11.1706.1706 |
0.377 |
|
| 2007 |
Lwin T, Hazlehurst LA, Li Z, Dessureault S, Sotomayor E, Moscinski LC, Dalton WS, Tao J. Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-kappaB (RelB/p52) in non-Hodgkin's lymphoma cells. Leukemia. 21: 1521-31. PMID 17476277 DOI: 10.1038/Sj.Leu.2404723 |
0.335 |
|
| 2007 |
Hazlehurst LA, Argilagos RF, Dalton WS. Beta1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells. British Journal of Haematology. 136: 269-75. PMID 17233818 DOI: 10.1111/j.1365-2141.2006.06435.x |
0.351 |
|
| 2007 |
Oliveira VA, Mathews L, Yarde D, Wang X, Boulware D, Hazlehurst LA, Chen D, Beg A, Dalton WS. NF-kB as a Regulator of FA/BRCA Gene Expression in Multiple Myeloma. Blood. 110: 3508-3508. DOI: 10.1182/Blood.V110.11.3508.3508 |
0.39 |
|
| 2006 |
Turner JG, Gump JL, Zhang C, Cook JM, Marchion D, Hazlehurst L, Munster P, Schell MJ, Dalton WS, Sullivan DM. ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood. 108: 3881-9. PMID 16917002 DOI: 10.1182/Blood-2005-10-009084 |
0.433 |
|
| 2006 |
Hazlehurst LA, Argilagos RF, Emmons M, Boulware D, Beam CA, Sullivan DM, Dalton WS. Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells. Cancer Research. 66: 2338-45. PMID 16489039 DOI: 10.1158/0008-5472.CAN-05-3256 |
0.346 |
|
| 2006 |
Yarde DN, Hazlehurst LA, Oliveira VA, Chen Q, Dalton WS. Bortezomib Enhances Melphalan Response by Altering Fanconi Anemia (FA)/BRCA Pathway Expression and Function. Blood. 108: 840-840. DOI: 10.1182/blood.V108.11.840.840 |
0.306 |
|
| 2006 |
Lwin T, Hazlehurst LA, Moscinski LC, Dalton WS, Tao J. Bone Marrow Stroma (BMS) Prevents Apoptosis of Lymphoma Cells by Upregulation of BMS-Derived B-Cell Activating Factor (BAFF) and Activation of NF-kB. Blood. 108: 2378-2378. DOI: 10.1182/blood.v108.11.2378.2378 |
0.39 |
|
| 2005 |
Chen Q, Van der Sluis PC, Boulware D, Hazlehurst LA, Dalton WS. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood. 106: 698-705. PMID 15802532 DOI: 10.1182/blood-2004-11-4286 |
0.358 |
|
| 2004 |
Dalton WS, Hazlehurst L, Shain K, Landowski T, Alsina M. Targeting the bone marrow microenvironment in hematologic malignancies. Seminars in Hematology. 41: 1-5. PMID 15190509 DOI: 10.1053/J.Seminhematol.2004.02.001 |
0.454 |
|
| 2004 |
Engel R, Valkov NI, Gump JL, Hazlehurst L, Dalton WS, Sullivan DM. The cytoplasmic trafficking of DNA topoisomerase IIalpha correlates with etoposide resistance in human myeloma cells. Experimental Cell Research. 295: 421-31. PMID 15093741 DOI: 10.1016/J.Yexcr.2004.01.012 |
0.445 |
|
| 2004 |
Hazlehurst LA, Alsina M, Hacker MP. Investigations on the Mechanisms of Resistance to Pixantrone in Tumor Cells. Blood. 104: 3402-3402. DOI: 10.1182/blood.v104.11.3402.3402 |
0.387 |
|
| 2004 |
Nimmanapalli R, Hazlehurst L, Enkemann S, Alsina M, Dalton WS. Bortezomib-Induced Reversal of CAM-DR Phenotype in Myeloma Is Associated with AKT and ERK1/2 Signaling. Blood. 104: 3357-3357. DOI: 10.1182/Blood.V104.11.3357.3357 |
0.483 |
|
| 2004 |
Chen Q, Van der Sluis PC, Hazlehurst L, Dalton WS. Enhanced DNA Repair Via Fanconi Anemia/BRCA Pathway Is Involved in Melphalan-Resistant Myeloma Cells. Blood. 104: 284-284. DOI: 10.1182/Blood.V104.11.284.284 |
0.449 |
|
| 2004 |
Alsina M, Nimmanapalli R, Paul MA, Elvira G, Hazlehurst L, Enkemann S, Craig B, Dalton WS. Influence of Fibronectin,(FN), Adhesion on Gene Expression Profiles, (GEP), of Isolated Patient Myeloma Cells. Blood. 104: 2345-2345. DOI: 10.1182/Blood.V104.11.2345.2345 |
0.46 |
|
| 2003 |
Hazlehurst LA, Enkemann SA, Beam CA, Argilagos RF, Painter J, Shain KH, Saporta S, Boulware D, Moscinski L, Alsina M, Dalton WS. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Research. 63: 7900-6. PMID 14633719 |
0.378 |
|
| 2003 |
Hazlehurst LA, Landowski TH, Dalton WS. Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death. Oncogene. 22: 7396-402. PMID 14576847 DOI: 10.1038/sj.onc.1206943 |
0.344 |
|
| 2001 |
Hazlehurst LA, Dalton WS. Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies. Cancer Metastasis Reviews. 20: 43-50. PMID 11831646 DOI: 10.1023/A:1013156407224 |
0.379 |
|
| 2001 |
Oshiro MM, Landowski TH, Catlett-Falcone R, Hazlehurst LA, Huang M, Jove R, Dalton WS. Inhibition of JAK kinase activity enhances Fas-mediated apoptosis but reduces cytotoxic activity of topoisomerase II inhibitors in U266 myeloma cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 7: 4262-71. PMID 11751528 |
0.35 |
|
| 2001 |
Damiano JS, Hazlehurst LA, Dalton WS. Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation. Leukemia. 15: 1232-9. PMID 11480565 DOI: 10.1038/Sj.Leu.2402179 |
0.512 |
|
| 2000 |
Anderson KC, Kyle RA, Dalton WS, Landowski T, Shain K, Jove R, Hazlehurst L, Berenson J. Multiple Myeloma: New Insights and Therapeutic Approaches. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 147-165. PMID 11701540 DOI: 10.1182/Asheducation-2000.1.147 |
0.462 |
|
| 2000 |
Hazlehurst LA, Damiano JS, Buyuksal I, Pledger WJ, Dalton WS. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene. 19: 4319-27. PMID 10980607 DOI: 10.1038/Sj.Onc.1203782 |
0.335 |
|
| 1999 |
Hazlehurst LA, Foley NE, Gleason-Guzman MC, Hacker MP, Cress AE, Greenberger LW, De Jong MC, Dalton WS. Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. Cancer Research. 59: 1021-8. PMID 10070958 |
0.349 |
|
| 1999 |
Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 93: 1658-67. PMID 10029595 |
0.341 |
|
| 1998 |
Hazlehurst LA, Gros P, Dalton WS. Chromosome mediated gene transfer of drug resistance to mitoxantrone. Anticancer Research. 18: 1005-10. PMID 9615755 |
0.312 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2009 |
Nair RR, Emmons MF, Cress AE, Argilagos RF, Lam K, Kerr WT, Wang HG, Dalton WS, Hazlehurst LA. HYD1-induced increase in reactive oxygen species leads to autophagy and necrotic cell death in multiple myeloma cells. Molecular Cancer Therapeutics. 8: 2441-51. PMID 19671765 DOI: 10.1158/1535-7163.Mct-09-0113 |
0.288 |
|
| 2007 |
Lwin T, Hazlehurst LA, Dessureault S, Lai R, Bai W, Sotomayor E, Moscinski LC, Dalton WS, Tao J. Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas. Blood. 110: 1631-8. PMID 17502456 DOI: 10.1182/Blood-2006-11-060350 |
0.288 |
|
| 2000 |
Hazlehurst LA, Wisner L, Storey JA, Sullivan DM, Dalton WS. Adhesion of U937 CELLS to fibronectin via βl integrins confers resistance to topoisomeraseii inhibitors and correlates with decreased DNA double strand breaks and topoisomerase Hβ activity Blood. 96. |
0.281 |
|
| 2009 |
Shain KH, Yarde DN, Meads MB, Huang M, Jove R, Hazlehurst LA, Dalton WS. Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Research. 69: 1009-15. PMID 19155309 DOI: 10.1158/0008-5472.CAN-08-2419 |
0.263 |
|
| 2001 |
Hazlehurst LA, Valkov N, Wisner L, Storey JA, Boulware D, Sullivan DM, Dalton WS. Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells. Blood. 98: 1897-903. PMID 11535527 DOI: 10.1182/blood.V98.6.1897 |
0.262 |
|
| 2023 |
Ivey AD, Fagan BM, Murthy P, Lotze MT, Zeh HJ, Hazlehurst LA, Geldenhuys WJ, Boone BA. Chloroquine reduces neutrophil extracellular trap (NET) formation through inhibition of peptidyl arginine deiminase 4 (PAD4). Clinical and Experimental Immunology. PMID 36655514 DOI: 10.1093/cei/uxad005 |
0.262 |
|
| 2009 |
Hazlehurst L, Hacker M. Drug Resistance Pharmacology. 371-385. DOI: 10.1016/B978-0-12-369521-5.00015-4 |
0.258 |
|
| 2021 |
Elzamzamy OM, Johnson BE, Chen WC, Hu G, Penner R, Hazlehurst LA. Transient Receptor Potential C 1/4/5 Is a Determinant of MTI-101 Induced Calcium Influx and Cell Death in Multiple Myeloma. Cells. 10. PMID 34199280 DOI: 10.3390/cells10061490 |
0.245 |
|
| 2021 |
Elzamzamy OM, Johnson BE, Chen WC, Hu G, Penner R, Hazlehurst LA. Transient Receptor Potential C 1/4/5 Is a Determinant of MTI-101 Induced Calcium Influx and Cell Death in Multiple Myeloma. Cells. 10. PMID 34199280 DOI: 10.3390/cells10061490 |
0.245 |
|
| 2017 |
Shay G, Tauro M, Loiodice F, Tortorella P, Sullivan DM, Hazlehurst LA, Lynch CC. Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironment. Oncotarget. PMID 28611279 DOI: 10.18632/oncotarget.18103 |
0.244 |
|
| 2019 |
Hayes KE, Batsomboon P, Chen WC, Johnson BD, Becker A, Eschrich S, Yang Y, Robart AR, Dudley GB, Geldenhuys WJ, Hazlehurst LA. Inhibition of the FAD containing ER oxidoreductin 1 (Ero1) protein by EN-460 as a strategy for treatment of multiple myeloma. Bioorganic & Medicinal Chemistry. PMID 30850265 DOI: 10.1016/J.Bmc.2019.02.016 |
0.24 |
|
| 2021 |
Jones CA, Hazlehurst LA. Role of Calcium Homeostasis in Modulating EMT in Cancer. Biomedicines. 9. PMID 34572386 DOI: 10.3390/biomedicines9091200 |
0.232 |
|
| 2016 |
Shay G, Lo C, Hazlehurst L, Lynch C. Host-derived MMP-13 promotes Multiple Myeloma skeletal colonization Bone Abstracts. DOI: 10.1530/Boneabs.5.P125 |
0.229 |
|
| 2011 |
Padron E, Hazlehurst LA, Pinilla-Ibarz J. Molecular Pathogenesis of BCR-ABL in Chronic Myeloid Leukemia Advances in Malignant Hematology. 62-70. DOI: 10.1002/9781444394016.ch4 |
0.229 |
|
| 2023 |
Marr KD, Gard JMC, Harryman WL, Keeswood EJ, Paxson AI, Wolgemuth C, Knudsen BS, Nagle RB, Hazlehurst L, Sorbellini M, Cress AE. Biophysical phenotype mixtures reveal advantages for tumor muscle invasion in vivo. Biophysical Journal. PMID 37766428 DOI: 10.1016/j.bpj.2023.09.016 |
0.216 |
|
| 2017 |
Geldenhuys WJ, Bergeron SA, Mullins JE, Aljammal R, Gaasch BL, Chen WC, Yun J, Hazlehurst LA. High-content screen using zebrafish (Danio rerio) embryos identifies a novel kinase activator and inhibitor. Bioorganic & Medicinal Chemistry Letters. PMID 28320616 DOI: 10.1016/J.Bmcl.2017.02.068 |
0.21 |
|
| 2011 |
Yanamandra N, Buzzeo RW, Gabriel M, Hazlehurst LA, Mari Y, Beaupre DM, Cuevas J. Tipifarnib-induced apoptosis in acute myeloid leukemia and multiple myeloma cells depends on Ca2+ influx through plasma membrane Ca2+ channels. The Journal of Pharmacology and Experimental Therapeutics. 337: 636-43. PMID 21378206 DOI: 10.1124/Jpet.110.172809 |
0.201 |
|
| 2022 |
Johnson BD, Kaulagari S, Chen WC, Hayes K, Geldenhuys WJ, Hazlehurst LA. Identification of Natural Product Sulfuretin Derivatives as Inhibitors for the Endoplasmic Reticulum Redox Protein ERO1α. Acs Bio & Med Chem Au. 2: 161-170. PMID 35892127 DOI: 10.1021/acsbiomedchemau.1c00062 |
0.197 |
|
| 2012 |
Riaz W, Pham J, Zhang L, Moscinski L, Hazlehurst LA, Emmons M, Sullivan DM, Shain KH, Lynch C, Binglin Y, Lin H, Baz R. Prognostic Significance of VLA4 and CD44 Expression by Flow Cytometry in Multiple Myeloma (MM) Blood. 120: 4975-4975. DOI: 10.1182/blood.V120.21.4975.4975 |
0.196 |
|
| 2020 |
Caulfield TR, Hayes KE, Qiu Y, Coban M, Seok Oh J, Lane AL, Yoshimitsu T, Hazlehurst L, Copland JA, Tun HW. A Virtual Screening Platform Identifies Chloroethylagelastatin A as a Potential Ribosomal Inhibitor. Biomolecules. 10. PMID 33027969 DOI: 10.3390/biom10101407 |
0.193 |
|
| 2006 |
Emmons M, Boulware D, Sullivan DM, Hazlehurst LA. Topoisomerase II beta levels are a determinant of melphalan-induced DNA crosslinks and sensitivity to cell death. Biochemical Pharmacology. 72: 11-8. PMID 16678798 DOI: 10.1016/j.bcp.2006.03.017 |
0.182 |
|
| 1995 |
Hazlehurst LA, Krapcho AP, Hacker MP. Comparison of AZA-anthracenedione-induced DNA damage and cytotoxicity in experimental tumor cells Biochemical Pharmacology. 50: 1087-1094. PMID 7575665 DOI: 10.1016/0006-2952(95)00246-V |
0.175 |
|
| 2023 |
Malla M, Kumar Deshkmukh S, Wu S, Samec T, Olevian D, Naili R, Bassel ER, Xiu J, Farrell A, Lenz HJ, Lou E, Goel S, Spetzler D, Goldberg RM, Hazlehurst L. Mesothelin expression correlates with elevated inhibitory immune activity in patients with colorectal cancer. Research Square. PMID 38234761 DOI: 10.21203/rs.3.rs-3787873/v1 |
0.17 |
|
| 2023 |
Newton E, Starcovic SA, Menze M, Konkle ME, Long TE, Hazlehurst LA, Huber JD, Robart AR, Geldenhuys WJ. Development of a fluorescence screening assay for binding partners of the iron-sulfur mitochondrial protein mitoNEET. Bioorganic & Medicinal Chemistry Letters. 129310. PMID 37137430 DOI: 10.1016/j.bmcl.2023.129310 |
0.158 |
|
| 2020 |
Johnson BD, Geldenhuys WJ, Hazlehurst LA. The Role of ERO1α in Modulating Cancer Progression and Immune Escape. Journal of Cancer Immunology. 2: 103-115. PMID 33615311 DOI: 10.33696/cancerimmunol.2.023 |
0.153 |
|
| 2020 |
Elzamzamy OM, Penner R, Hazlehurst LA. The Role of TRPC1 in Modulating Cancer Progression. Cells. 9. PMID 32046188 DOI: 10.3390/cells9020388 |
0.14 |
|
| 2008 |
Koomen JM, Haura EB, Bepler G, Sutphen R, Remily-Wood ER, Benson K, Hussein M, Hazlehurst LA, Yeatman TJ, Hildreth LT, Sellers TA, Jacobsen PB, Fenstermacher DA, Dalton WS. Proteomic contributions to personalized cancer care. Molecular & Cellular Proteomics : McP. 7: 1780-94. PMID 18664563 DOI: 10.1074/Mcp.R800002-Mcp200 |
0.125 |
|
| 1995 |
Hazlehurst LA, Krapcho AP, Hacker MP. Correlation of DNA reactivity and cytotoxicity of a new class of anticancer agents: Aza-anthracenediones Cancer Letters. 91: 115-124. PMID 7750086 DOI: 10.1016/0304-3835(95)91035-5 |
0.123 |
|
| 2019 |
Geldenhuys WJ, Long TE, Saralkar P, Iwasaki T, Nuñez RAA, Nair RR, Konkle ME, Menze MA, Pinti MV, Hollander JM, Hazlehurst LA, Robart AR. Crystal structure of the mitochondrial protein mitoNEET bound to a benze-sulfonide ligand. Communications Chemistry. 2. PMID 32382661 DOI: 10.1038/s42004-019-0172-x |
0.12 |
|
| 2022 |
Shultz C, Gates C, Petros W, Ross K, Veltri L, Craig M, Wen S, Primerano DA, Hazlehurst L, Denvir J, Sdrimas K. Association of genetic variants and survival in patients with acute myeloid leukemia in rural Appalachia. Cancer Reports (Hoboken, N.J.). e1746. PMID 36382570 DOI: 10.1002/cnr2.1746 |
0.08 |
|
| 2009 |
Hazlehurst LA. Detection of DNA damage induced by topoisomerase II inhibitors, gamma radiation and crosslinking agents using the comet assay. Methods in Molecular Biology (Clifton, N.J.). 523: 169-76. PMID 19381939 DOI: 10.1007/978-1-59745-190-1_12 |
0.077 |
|
| 2008 |
Kamath V, Goldgof D, Argilagos R, Hazlehurst L, Eschrich S. Towards a framework for analysis of biophotonic images of mouse models of cancer. Conference Proceedings : ... Annual International Conference of the Ieee Engineering in Medicine and Biology Society. Ieee Engineering in Medicine and Biology Society. Annual Conference. 2008: 3079-82. PMID 19163357 DOI: 10.1109/IEMBS.2008.4649854 |
0.068 |
|
| 2021 |
Saralkar P, Mdzinarishvili A, Arsiwala TA, Lee YK, Sullivan PG, Pinti MV, Hollander JM, Kelley EE, Ren X, Hu H, Simpkins J, Brown C, Hazlehurst LE, Huber JD, Geldenhuys WJ. The Mitochondrial mitoNEET Ligand NL-1 Is Protective in a Murine Model of Transient Cerebral Ischemic Stroke. Pharmaceutical Research. PMID 33982226 DOI: 10.1007/s11095-021-03046-4 |
0.065 |
|
| 1994 |
Hazlehurst L, Woods M. Automated rivet interference inspection system Sae Technical Papers. DOI: 10.4271/941842 |
0.045 |
|
| Hide low-probability matches. |